Effects of miglitol versus nateglinide on postprandial hyperglycaemia and the triglyceride/high density lipoprotein (HDL) cholesterol ratio in diabetic patients with stable coronary artery disease (CAD)

Trial Profile

Effects of miglitol versus nateglinide on postprandial hyperglycaemia and the triglyceride/high density lipoprotein (HDL) cholesterol ratio in diabetic patients with stable coronary artery disease (CAD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2013

At a glance

  • Drugs Miglitol (Primary) ; Nateglinide
  • Indications Coronary artery disease; Diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2013 New trial record
    • 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top